Understand the cardiovascular partnering landscape using intelligence from 664 real-world collaboration and licensing deals.
Cardiovascular Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 664 partnering deals involving cardiovascular assets, technologies and development programs.
Cardiovascular partnering spans a diverse range of therapeutic indications, technologies and stages of development, from early research collaborations through to licensing and commercialization agreements.
The report brings this activity together in one resource, enabling users to understand who is partnering, which cardiovascular opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, individual transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in cardiovascular partnering.
This provides real-world reference points for internal benchmarking, opportunity assessment and deal preparation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
The report analyzes deals by cardiovascular therapeutic indication, allowing users to move beyond broad market-level benchmarks and investigate the transactions most relevant to a particular program or area of strategic interest.
Combined with analysis by technology and development stage, this enables users to develop a more focused view of comparable deal activity.
Identify comparable cardiovascular deals, prospective partners and relevant transaction structures.
Search and Evaluation teams
Understand which companies are actively seeking cardiovascular opportunities across particular indications, technologies and stages of development.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable cardiovascular assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building cardiovascular pipelines through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
The briefing applies the underlying cardiovascular deal intelligence to the customer's own asset, technology, indication or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Cardiovascular Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 664 partnering deals involving cardiovascular assets, technologies and development programs.
Cardiovascular partnering spans a diverse range of therapeutic indications, technologies and stages of development, from early research collaborations through to licensing and commercialization agreements.
The report brings this activity together in one resource, enabling users to understand who is partnering, which cardiovascular opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, individual transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in cardiovascular partnering.
Understand the cardiovascular partnering landscape
The report analyzes cardiovascular dealmaking from 2016 to 2026, including:
- Trends in cardiovascular partnering by year
- Deal activity by deal type
- Industry sector
- Stage of development at the time of partnering
- Technology type
- Cardiovascular therapeutic indication
- Most active cardiovascular dealmakers
- Leading deals by disclosed value
- How cardiovascular partnering activity is evolving
Benchmark cardiovascular deal financials
Financial terms can vary considerably according to the nature of the cardiovascular asset, development stage, technology, rights granted and transaction structure.The report provides dedicated analysis of disclosed financial terms, including:
- Headline deal values
- Upfront payments
- Milestone payments
- Royalty rates
This provides real-world reference points for internal benchmarking, opportunity assessment and deal preparation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading cardiovascular dealmakers and prospective partners
The report identifies the most active companies in cardiovascular partnering and provides transaction histories that enable users to investigate their previous activity.This can help users identify:
- Companies actively seeking cardiovascular opportunities
- Prospective licensing and collaboration partners
- Organizations repeatedly partnering in particular cardiovascular indications
- Companies active at relevant stages of development
- Dealmakers demonstrating interest in specific technologies or approaches
- Competitors pursuing similar external innovation strategies
Compare partnering activity across cardiovascular indications
Cardiovascular disease encompasses multiple distinct therapeutic areas and development strategies.The report analyzes deals by cardiovascular therapeutic indication, allowing users to move beyond broad market-level benchmarks and investigate the transactions most relevant to a particular program or area of strategic interest.
Combined with analysis by technology and development stage, this enables users to develop a more focused view of comparable deal activity.
Understand how cardiovascular agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.Depending on the transaction and available disclosure, users can investigate areas including:
- Rights granted and retained
- Research and development responsibilities
- Licensing rights
- Exclusivity
- Geographic rights
- Intellectual property
- Development and regulatory obligations
- Manufacturing and supply responsibilities
- Commercialization rights
- Financial consideration
- Milestones and royalties
- Governance
- Term and termination provisions
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected cardiovascular transactions.These agreements can provide significantly more detail than headline announcements alone, helping users examine how companies have documented areas such as:
- Scope of rights
- Development obligations
- Intellectual property
- Exclusivity
- Financial terms
- Milestone triggers
- Royalty provisions
- Commercialization rights
- Termination and other negotiated provisions
Comprehensive cardiovascular deal directory
The report includes a comprehensive directory of 664 cardiovascular collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.Deals can be reviewed by:
- Company
- Technology type
- Therapeutic indication
- Contract availability
Who should use this report?
Business Development and Licensing teamsIdentify comparable cardiovascular deals, prospective partners and relevant transaction structures.
Search and Evaluation teams
Understand which companies are actively seeking cardiovascular opportunities across particular indications, technologies and stages of development.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable cardiovascular assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building cardiovascular pipelines through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide cardiovascular intelligence into company-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying cardiovascular deal intelligence to the customer's own asset, technology, indication or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in cardiovascular dealmaking
Chapter 3 - Financial deal terms for cardiovascular partnering
Chapter 4 - Leading cardiovascular deals and dealmakers
Chapter 5 - Cardiovascular contract document directory
Chapter 6 - Cardiovascular dealmaking by therapeutic target
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3DR Labs
- 4D Molecular Therapeutics
- 23andMe
- A*STAR Agency for Science
- Technology and Research
- Abbisko Therapeutics
- Abbott Laboratories
- Abbott Vascular Devices
- Abbvie
- Acandis
- Acasti Pharma
- Accenture
- Access Scientific
- AccuLine
- AccurKardia
- ACEA Biosciences
- Actelion
- Acutus Medical
- ADAS 3D Medical
- AddUp
- Admera Health
- Advanced BioInformatics
- Advanced Catheter Therapies
- Aegerion Pharmaceutical
- Affinia Therapeutics
- AFFiRiS
- Agepha Pharma
- AgeX Therapeutics
- Ahngook Pharmaceuticals
- Aidoc
- Akcea Therapeutics
- Akebia Therapeutics
- Albert Einstein College of Medicine
- Aleris
- Alexion Pharmaceuticals
- Alibaba Health
- AliveCor
- ALK-Abello
- Allelica
- Allscripts
- Alnylam Pharmaceuticals
- Altamira Therapeutics
- Amarin
- Ambry Genetics
- American College of Cardiology
- American Heart Association
- American Pharmaceutical Association
- Amgen
- AMO Pharma
- Amryt Pharma
- AnaBios
- Analog Devices
- AnaMar
- Ancora Heart
- Andelyn Biosciences
- AnGes MG
- Angiogenesis Foundation
- Angion Biomedica
- Angionetics
- AngioSoma
- Antares Pharma
- Antaros Medical
- Anthos Therapeutics
- Anumana
- Apicore
- Aplagon
- Apollo Therapeutics
- Apotex
- Apple
- Aptahem
- Aralez Pharmaceuticals
- Ardelyx
- Arena Pharmaceuticals
- argenx
- Argo Biopharma
- Argon Medical Devices
- Armatus Bio
- Arrowhead Pharmaceuticals
- Asahi Kasei
- Ascendis Pharma
- Aspire Health Science
- Astellas Pharma
- AstraZeneca
- AtCor Medical
- Atelerix
- Athena Bioscience
- Athersys
- Attune Medical
- Audentes Therapeutics
- Australian Research Council
- Avania
- Avery Therapeutics
- Avicenna Technology
- Avidity Biosciences
- Avinger
- Avrobio
- Axiogenesis
- Axol Bioscience
- Axxam
- Aziyo Biologics
- Azurity Pharmaceuticals
- B-Secur
- Babraham Institute
- Bausch Health Companies
- Baxter International
- Bayer
- Bay Labs
- Baylor College
- Beam Therapeutics
- Beijing SL Pharma
- Bened Biomedical
- BenevolentAI
- Beth Israel Deaconess Medical Center
- Bicycle Therapeutics
- BioCardia
- Biocon
- Biofourmis
- BioIntelliSense
- BioLamina
- BIOLIFE4D
- BioMarin Pharmaceutical
- BioMatrix Specialty Pharmacy
- Biomerics
- BioPep
- BioSig Technologies
- Biotheus
- Biotricity
- Biotronik
- BioVectra
- Bioventix
- Biovic Sdn bhd
- Bird Foundation
- Bitterroot Bio
- BiVACOR
- BlueRock Therapeutics
- Blue Water Biotech
- Boehringer Ingelheim
- Boston Medical Center
- Boston Pharmaceuticals
- Boston Scientific
- Braveheart Bio
- BridgeBio Pharma
- Brigham and Women's Hospital
- Brigham Young University
- BrightInsight
- Bristol-Myers Squibb
- Broad Institute
- Broncus Technologies
- Brooks Automation
- Butterfly Network
- Cadila Pharmaceuticals
- Caerus Strength
- Caladrius Biosciences
- California Institute of Technology
- Canadian Institutes of Health Research
- Cap Alter Pharma
- Capricor Therapeutics
- Capsule Tech
- CardiaCare
- Cardiac Insight
- Cardialen
- CardieX
- CardiNor
- CardioFocus
- Cardiogen Sciences
- Cardiomatics
- Cardiome Pharma
- Cardiovascular Research Foundation
- Cardiovascular Solutions of Central Mississippi
- Cardiovascular Systems
- Cardiowise
- Cardurion Pharmaceuticals
- Carestream Health
- CareTaker Medical
- Caristo Diagnostics
- Carmat
- Carmel Pharma
- Carrum Health
- Case Western Reserve University
- Catalent
- Catheter Precision
- CB Scientific
- Ceapro
- Cedars-Sinai Medical Center
- Celanese
- Cell and Gene Therapy Catapult
- CELLINK
- CellProThera
- Cell Therapy
- Celltrion
- Centers for Disease Control and Prevention
- Cevec Pharmaceuticals
- Chang Gung University
- Chansu Vascular Technologies
- Charles River Laboratories
- Chemify
- Children's Heart Foundation
- Children's Hospital Boston
- Children's Hospital of Orange County
- Children's Hospital of Philadelphia
- Children's Medical Research Institute
- Children's Minnesota
- China Grand Pharmaceutical
- China Resources Sanjiu Medical and Pharmaceutical
- Chinese Society of Cardiology
- Cholesgen
- CinCor Pharma
- Cipherome
- Cipla
- Circle cardiovascular imaging
- Citius Pharmaceuticals
- Civica Rx
- Clario
- Cleveland Clinic
- Clinical Consultants International
- Closed Loop Medicine
- Coala Life
- Columbia University Medical Center
- CoreRx Pharma
- Corindus Vascular Robotics
- Cornell University
- Correvio Pharma
- Corvidia Therapeutics
- CORXEL Pharmaceuticals
- Cosette Pharmaceuticals
- Covalon Technologies
- Creative Medical Technologies
- CRISPR Therapeutics
- Critical Diagnostics
- Crown Bioscience
- CSL
- CSPC Pharmaceutical Group
- Curadev Pharma
- CVie
- CyberHeart
- Cyclenium Pharma
- Cyclerion Therapeutics
- Cytokinetics
- Daiichi Sankyo
- Dalhousie University
- Dassault Systems
- Datos Health
- DaVinci Biomedical Research Products
- deCODE Genetics
- Deep Apple Therapeutics
- Denovium
- Denovo Biopharma
- Department of Defense
- Dewpoint Therapeutics
- DHR Health
- Diablo Clinical Research
- DiA Imaging Analysis
- Dicerna Pharmaceuticals
- DiNAQOR
- DKSH
- DNAnexus
- Dogma Therapeutics
- Dorizoe Lifesciences
- Dr. Reddy's Laboratories
- Duke-NUS Graduate Medical School Singapore
- Duke Clinical Research Institute (DCRI)
- Duke University
- Duke University Medical Center
- Dyno Therapeutics
- Eccogene
- EchoNous
- Edwards Lifesciences
- eGenesis
- Egnite
- Eidos Therapeutics
- Eko
- Eko Health
- ELC Group
- Eledon Pharmaceuticals
- ELEO
- Eleven Biotherapeutics
- Elexopharm
- Eligo Bioscience
- Eli Lilly
- Embolx
- Emory University
- Enamine
- Enogenesis
- Enzolytics
- Epsilon
- Er-Kim
- Erasmus University Medical Center
- ERS Genomics
- Esperion Therapeutics
- Espero Biopharma
- Essential Pharma
- Ethris
- Etiometry
- Eureka Eurostars
- European Innovation Council
- European Wellness Biomedical Group
- Everest Medicines
- Evogene
- Evotec
- Evox Therapeutics
- Exo
- Exscientia
- Feinstein Institute for Medical Research
- FEops
- FibriCheck
- Fine Foods & Pharmaceuticals N.T.M.
- FitBit
- Flagship Biosciences
- Flagship Pioneering
- Food and Drug Administration (FDA)
- Forcefield Therapeutics
- Foresee Pharmaceuticals
- Forge Biologics
- Fortress Biotech
- Freeline Therapeutics
- Frontier Biotech
- Fujifilm
- Fujifilm medical systems
- Fuji Yakuhin
- Fulcrum Therapeutics
- G3 Pharmaceuticals
- G3 Therapeutics
- Galmed Pharmaceuticals
- Gatehouse Bio
- GC Pharma
- GE Healthcare
- Geisinger Medical Center
- Gemphire
- GenEditBio
- Genentech
- Genevant Sciences
- Genome Biologics
- Genomic Vision
- Gensaic
- George Clinical
- George Medicines
- Georgetown University
- Georgia Institute of Technology
- German Ministry for Education and Research
- Gestion Univalor
- Getinge
- Gibraltar Health Authority
- Global Genomics Group
- GNS Healthcare
- Gossamer Bio
- Government of South Korea
- Grunenthal
- GS
- GSK
- Guangdong Provincial People's Hospital
- Hainan Sihuan Pharmaceutical
- Hancock Jaffe Laboratories
- Handok Pharmaceuticals
- Hanmi Pharmaceutical
- Harvard Pilgrim Health Care
- Harvard Stem Cell Institute
- Harvard University
- Hasten Biopharmaceutic
- HAYA Therapeutics
- HCM Registry
- Healios K.K.
- Healium Medical
- Health Recovery Solutions
- Health Sciences Research Institute Germans Trias i Pujol Foundation
- HeartBeam
- HeartBeat.bio
- Heartflow
- HeartHero
- Heart Rhythm Clinical Research Solutions
- HeartSciences
- Heartseed
- Helix
- HELP Therapeutics
- Hemostemix
- Henlius Biotech
- Henry Ford Health System
- Heqet Therapeutics
- Hetero Labs
- High Desert Heart Institute
- HighLife
- Hikma Pharmaceuticals
- HitGen
- HLS Therapeutics
- Holberg EEG
- HoliStick Medical
- Hologic
- Horizon Discovery
- Horizon Europe
- Hospital for Sick Children
- Huadong Medicine
- Huami
- Huapont Pharma
- Humacyte
- Human Biosystems
- Hyloris Pharmaceuticals
- Icahn School of Medicine at Mount Sinai
- iCardiac Technologies
- Idorsia
- iECURE
- ii Ventures
- Illumina
- ImagineMIC
- IME Medical Electrospinning
- ImpediMed
- Imperial College London
- Imricor Medical Systems
- InCarda Therapeutics
- Indiana University
- InfoBionic.Ai
- inHealth Medical
- inHEART
- Innosuisse
- Innovate UK
- Innovation Network Corporation
- Innova Vascular
- Innovent Biologics
- InQB8 Medical Technologies
- Insilico Biotechnology
- Insilico Medicine
- Inspyr Therapeutics
- Institute of Human Virology
- Integrated DNA Technologies
- Intermountain Healthcare
- International Society of Heart and Lung Transplantation
- Ionis Pharmaceuticals
- I Peace
- IQVIA
- iRhythm Technology
- Istituti Clinici Scientifici Maugeria
- Itochu
- Ixaka
- Jackson Laboratory
- Jacksonville Pharmaceuticals
- Jana Care
- JanOne
- Janssen Human Microbiome Institute
- Janssen Pharmaceuticals
- Janssen Research & Development
- Jarvik Heart
- JenaValve Technology
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Hengrui Pharmaceuticals
- Ji Xing Pharmaceuticals
- Johns Hopkins Medicine (JHM)
- Johns Hopkins University
- Johnson & Johnson
- Juntendo University
- Kahn-Sagol-Maccabi
- Kalos Medical
- Kantonsspital St. Gallen
- Kastle Therapeutics
- Keystone Heart
- Kiniksa Pharmaceuticals
- Kiromic Biopharma
- Kissei Pharmaceutical
- Kitov Pharma
- Korro Bio
- Kowa
- Kuhnil Pharmaceuticals
- Kyoto University
- Kyowa Hakko Kirin
- Kyttaro
- Laboratory Corporation of America
- La Jolla Capital
- La Jolla Pharmaceutical
- Lannett
- Lantheus Medical Imaging
- Laurel Bridge Software
- Lee's Pharmaceutical
- Leiden University
- Leonhardt's Launchpads
- LEO Pharma
- Leviticus Cardio
- LEXEO Therapeutics
- Lexicon Pharmaceuticals
- Lexington Biosciences
- LianBio
- LIB Therapeutics
- LifeQ
- LifeStrands Genomics
- LifeTech Scientific
- LifeWatch Services
- Ligand Pharmaceuticals
- LindaCare
- Lipigon Pharmaceuticals
- Longeveron
- Lonza
- Lotus Pharmaceuticals
- LSU Health Sciences Center
- LUCA Science
- Lund University
- Luscii
- mAbsolve
- Magnesium Elektron
- Mallinckrodt Pharmaceuticals
- Marizyme
- Marpai
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Max Biopharma
- Mayo Clinic
- McGill University
- MD Anderson Cancer Center
- MDF Instruments
- Medable
- MedAxiom
- MedCision
- Medera
- Medicardia Health
- MediciNova
- Medicure
- MedImmune
- Medipal Holdings
- MediSafe
- Mediso
- Medison Pharma
- Meditrial Europe
- Medtronic
- Melinta Therapeutics
- Menarini
- Mentice
- Merck and Co
- Merck KGaA
- Mesoblast
- Mespere LifeSciences
- Metaba
- MetaSight Diagnostics
- Metrion Biosciences
- Micro Interventional Devices
- Milestone Pharmaceuticals
- Minnetronix
- Mochida Pharmaceutical
- Moderna
- Molecular Stethoscope
- Monash University
- Montefiore Health System
- Montreal Heart Institute
- Mperia Therapeutics
- Mpirik
- Munich Reinsurance Company
- Myant
- Myocarditis Foundation
- MyoKardia
- Myriad RBM
- N8 Medical
- Nagoya University Graduate School of Medicine
- NAMSA
- Nano-X Imaging
- NanoMosaic
- NanoSurface Biomedical
- NanoVation Therapeutics
- NASA
- Nashville Biosciences
- National Cancer Center
- National Cancer Institute
- National Center for Cardiovascular Diseases
- National Cerebral and Cardiovascular Disease Research Center
- National Heart
- Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institute on Aging
- National Institutes of Health
- National Organization for Rare Disorders
- National Physical Laboratory
- National University of Ireland
- Galway (NUI Galway)
- Nationwide Children’s Hospital
- Natus Medical
- Ncardia
- NeoChord
- Neomorph
- Neovasc
- Neurimmune Therapeutics
- NeuroproteXeon
- New American Therapeutics
- NewAmsterdam Pharma
- New Wave Ventures
- New York Institute of Technology
- New York University
- NGM Biopharmaceuticals
- NHS Scotland
- Nightingale Health
- NIMIUM Therapeutics
- Ninety One
- Nissan Chemical Industries
- North Carolina State University
- Northwestern Medicine Bluhm Cardiovascular Institute
- Northwestern Medicine Developmental Therapeutics Institute
- Northwestern University
- NovalGen
- Novartis
- Novocardia
- Novoheart
- Novo Integrated Sciences
- Novo Nordisk
- Novostia
- NTT Data
- NTT Medical Center Tokyo
- Numares
- Numerate
- NuvoAir
- Nxera Pharma
- Octapharma
- Ohio State University
- OliX Pharmaceuticals
- Oloker Therapeutics
- OMEICOS Therapeutics
- Omron
- OncoImmune
- One Drop
- Opsens
- OptiBiotix
- Optina Diagnostics
- Opus Medical
- Orchestra BioMed
- Orebro University
- Organicell Regenerative Medicine
- Orient EuroPharma
- ORIG3N
- Oscor
- OSE Immunotherapeutics
- Otsuka
- Ovation
- Owkin
- PaceMate
- Paion
- Paragonix Technologies
- Paraza Pharma
- Paul G Allen Family Foundation
- Peijia Medical
- Peking University
- Penn Medicine
- PeptiDream
- Pfizer
- PharmAbcine
- Pharmabiota
- Pharmanovia
- Pharma Scientific Research
- Pharmazz
- Pharnext
- PhaseBio Pharmaceuticals
- Phibro Animal Health
- Philips
- Phlox Therapeutics
- PhoreMost
- Photys Therapeutics
- PhysIQ
- Pierre Fabre
- Pilloxa
- PlaqueTec
- Pluriomics
- Pluristem Therapeutics
- Pohl Boskamp
- Population Health Research Institute
- Precision BioSciences
- Precision Image Analysis
- Premier Inc
- Prevail InfoWorks
- Prevencio
- Primary Peptides
- Primevera Therapeutics
- Primordial Genetics
- Procella Therapeutics
- Profil Institute for Clinical Research
- ProFound Therapeutics
- Profusa
- Project HOPE
- ProtoKinetix
- PulseCath
- Punjab Province
- Qilu Pharmaceutical
- Qingdao Primedicine Pharmaceutical
- Qualigen
- Quercis Pharma
- Quest Diagnostics
- Quotient Therapeutics
- Rain Oncology
- Rancho Santa Fe Bio
- Recordati
- ReCor Medical
- Redoxis
- Redwire
- Reemo Health
- ReFlow Medical
- Regenerative Care Network
- Regenerative Medicine of Latin America
- Regeneron Pharmaceuticals
- Regenxbio
- Regio Biosciences
- Rejuvenate Bio
- Relaxera Pharmazeutische
- Reliance Life Sciences
- Renova Therapeutics
- Repair Biotechnologies
- Replicate Bioscience
- Research Development Foundation
- Respira Therapeutics
- Resverlogix
- Retia Medical
- Revive Therapeutics
- Rexgenero
- Rex Medical
- Rigel Pharmaceuticals
- Riparian Pharmaceuticals
- Roche
- Roche Diagnostics
- Rocket Pharmaceuticals
- Roivant Sciences
- RoosterBio
- Royal Philips Electronics
- RTW Investments
- Rutgers University
- SACCO
- Salipro Biotech
- Samsung Biologics
- Samsung Electronics
- Sanacor
- Sana Klinikum Offenbach
- SandboxAQ
- Sandoz
- SanegeneBio
- Sanofi
- Sarepta Therapeutics
- Sarfez Pharmaceuticals
- Saturnus Bio
- SCIMAGE
- ScinoPharm Taiwan
- Scipher Medicine
- Sciwind Biosciences
- Scohia Pharma
- scPharmaceuticals
- Seattle Childrens Research Institute
- Secant Medical
- Secarna Pharmaceuticals
- Sema4
- Semmelweis University
- Senti Biosciences
- Septerna
- Seqirus
- SERB Pharmaceuticals
- SFJ Pharmaceuticals
- Shanghai Argo Biopharmaceutical
- Shanghai Model Organisms Center
- Shenzhen Salubris Pharmaceuticals
- Shenzhen Semacare Medical Technology
- Shimadzu
- Shire Pharmaceuticals
- Siemens Healthineers
- SignPath Pharmaceuticals
- Silence Therapeutics
- Sinomed
- Sirius Therapeutics
- Sirtex Medical
- SkylineDX
- Skyline Therapeutics
- SmartCella
- Smartwise
- SNBL CPC
- Societal CDMO
- Society of NeuroInterventional Surgery
- Society of Vascular and Interventional Neurology
- Solid Biosciences
- SomaLogic
- SonoScape Medical
- SOPHiA Genetics
- Sosei
- Sosei Heptares
- Soufflé Therapeutics
- Soundbite Medical
- Southwest Research Institute
- Southwest Transplant Alliance
- Spacelabs Healthcare
- Spanish National Research Council
- Sphingotec
- SQI Diagnostics
- SQ Innovation
- Standard BioTools
- Stanford University
- Stanford University School of Medicine
- Staten Biotechnology
- Stealth BioTherapeutics
- StemCardia
- Stempeutics
- STENTiT
- Stereotaxis
- StrideBio
- Sumocor
- Sunshine Lake Pharma
- Surge Cardiovascular
- SurModics
- Suzhou Ribo Life Sciences
- Suzhou Siran Biotechnology
- Swedish Bactiguard
- SymphonyAI
- SynAct Pharma
- Syneos Health
- Syntach
- Syntactx
- Takeda Pharmaceutical
- Talis Biomedical
- TARA Biosystems
- Taros Chemicals
- Tasly Pharmaceuticals
- Tata Chemicals
- Teleflex
- Tempus
- Tenaya Therapeutics
- Terason
- Terumo
- Terumo Aortic
- Terumo Cardiovascular Systems
- Teson Pharma
- Texas Instruments
- TGen Drug Development
- The Foundry
- TheraVasc
- Thermo Fisher Scientific
- The University of Chicago Medicine
- Third Pole Therapeutics
- Thryv Therapeutics
- Tissue Dynamics
- Toolgen
- Topstone Research
- Toray
- toSense
- Transgenomic
- TriHealth
- Triple Ring Technologies
- Tris Pharma
- TTP Group
- twoXAR
- UAB Research Foundation
- Ubiquigent
- Ultragenyx Pharmaceuticals
- UltraSight
- Ultromics
- Unilife
- UniQure
- United Imaging Healthcare
- United Therapeutics
- University College London
- University of Alabama
- University of Bern
- University of British Columbia
- University of California
- San Diego
- University of California Los Angeles
- University of California San Francisco
- University of Cambridge
- University of Cincinnati
- University of Colorado
- University of Erlangen
- University of Glasgow
- University of Iowa
- University of Lausanne
- University of Manchester
- University of Maryland
- University of Miami
- University of Nebraska
- University of Oslo
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of the Highlands and Islands
- University of Utah Research Foundation
- University of Washington
- University of West Indies
- University of Wisconsin-Madison
- Unnatural Products
- Us2.ai
- Valo Health
- Vanderbilt University
- Variant Bio
- Vascugen
- Vascular Flow Technologies
- Vasomune Therapeutics
- Vastrax
- VectraCor
- Venturis Therapeutics
- Venus Medtech
- Verantos
- Verdiva Bio
- Verily
- Verizon
- Verve Therapeutics
- VFLO Medical
- Viatris
- Vifor Pharma
- Vince & Associates Clinical Research
- Vincere Biosciences
- Visirna Therapeutics
- Vitro Biopharma
- Viva Biotech
- VivaQuant
- Vivasc Therapeutics
- VivoSense
- Viz.ai
- Vizient
- VolitionRX
- VOTIS Subdermal Imaging Technologies
- Voyager Therapeutics
- Wacker Biotech
- Wake Forest University
- WakeMed Health & Hospitals
- Wallace H. Coulter Foundation
- Washington University in St Louis
- Weill Cornell Medical College
- Weizmann Institute
- WellDoc
- Western New England University
- West Pharmaceutical Services
- Windtree Therapeutics
- Winthrop-University Hospital
- World Heart Federation
- WraSer Pharmaceuticals
- Xentria
- Xspire Pharma
- XyloCor Therapeutics
- Yale School of Medicine
- Yale University
- YolTech Therapeutics
- ZAO Firma Euroservice
- ZeClinics
- Zelira Therapeutics
- Zhittya Genesis Medicine
- Zoll Medical
- Zora Biosciences
- Zylox Tonbridge Medical Technology Co
- Ltd
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
